[Personal experience with the use of human recombinant erythropoietin in the treatment of anemia in children with chronic renal insufficiency].
The authors analyze the course of treatment with human recombinant erythropoietin (rHuEPO) in five children in the preterminal stage of chronic renal insufficiency and one premature infant with a low birth weight and anaemia and acute renal insufficiency. rHuEPO was administered, 50-100 u./kg, by the s.c. route 2-3X per week. During the first month of treatment the haemoglobin rose from 7.0 dag/l to 8.2 dag/l and persisted at this level approximately to the third month of treatment. The haematocrit reached values of 0.30 during the 4th month of therapy when the authors observed also the maximum increase of reticulocytes (20%). The authors did not find a marked decline of iron and ferritin concentrations. In the child with a low birth weight treatment with rHuEPO was started at the age of six weeks and the age haemogram was favourably influenced already after four weeks of treatment with rHuEPO.
Podracká
L
L
Detská klinika Lekárskej fakulty Univerzity P. J. Safárika, Kosice.
Sasinka
M
M
Roland
R
R
Böör
A
A
D000740:Anemia / Q000209:etiology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin
Nase skúsenosti s pouzitím l'udského rekombinantného erytropoetínu v liecbe anémie u detí s CHRI.